Skip to content | Change text size
 

A/Prof Susan A. Charman

Photo of Associate Professor Susan Charman, Pharmaceutics

Associate Professor in Pharmaceutics

Director, Centre for Drug Candidate Optimisation

BSc., Florida State Univ., PhD, Univ. Florida

Phone: +61 3 9903 9626
Fax: +61 3 9903 9627
email: Susan.Charman@pharm.monash.edu.au

General Research Interests

  • Physicochemical and biopharmaceutical screening of investigational compounds as a guide to rational lead compound selection and optimisation
  • Physicochemical and formulation factors affecting the absorption and bioavailability of orally administered drugs
  • Lymphatic absorption and transport of protein drugs after subcutaneous administration

Significant Publications

  1. D. Creek, W.N. Charman, F.C.K. Chiu, R.J. Prankerd, Y. Dong, J.L. Vennerstrom, S.A. Charman. Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials. (2008) Antimicrobial Agents and Chemotherapy, 52(4), 1291-1296.
  2. L. Zhou, A. Alker, A. Ruf, X. Wang, F.C.K. Chiu, J. Morizzi, S.A. Charman, W.N. Charman, C. Scheurer, S. Wittlin, Y. Dong, D. Hunziker, J. L. Vennerstrom. Chracterization of the two major CYP450 metabolties of ozonide (1,2,4-trioxolane) OZ277 (2008) Bioorganic & Medicinal Chemistry Letters, 18, 1555-1558.
  3. K. Katneni, S.A. Charman, C.J.H. Porter. Use of plasma proteins as solubilizing agents in in vitro permeability experiments: correction for unbound drug concentration using the reciprocal permeability approach. (2008) Journal of Pharmaceutical Sciences, 97(1), 209-224.
  4. J.A. Nicolazzo,  T. Nguyen, K. Katneni, J. Steuten, G. Smith, B. Jarrott, J. Callaway, S.A. Charman. Pharmacokinetics and brain uptake of AM-36, a novel neuroprotective agent, following intravenous administration to rats. (2008) Journal of Pharmacy and Pharmacology 60, 171-178.
  5.  J. Kota, K. Machavaram, D. McLennan, G. Edwards, C.J.H. Porter, S.A. Charman. Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepetin alfa using a sheep model. (2007) Drug Metabolism and Disposition, 35(12) 2211-2217.
  6. X. Wang, Y. Dong, S. Wittlin, D. Creek, J. Chollet, S. Charman, J. S. Tomas, C. Scheurer, C. Snyder and J. Vennerstrom. Spiro- and dispiro-1,2-dioxolanes: Contribution of iron (II) - mediated one-electron vs two-electron reduction to the activity of antimalarial peroxides. (2007) Journal of Medicinal Chemistry, 50, 5840-5847.
  7. D. Creek, W.N. Charman, F.C.K. Chiu, R. Prankerd, K.J. McCullough, Y. Dong, J.L. Vennerstrom, S.A. Charman.  Iron-Mediated Degredation Kinetics of Substituted Dispiro-1,2,4-trioxolane Antimalarials. (2007) Journal of Pharmaceutical Sciences, 96(11), 2945-2956.
  8. Y. Dong, D. Creek, L. Chollet, H.Matile, S.A. Charman, S. Wittlin, J.K. Wood,  J.L. Vennerstrom. Comparative antimalarial activities of six pairs of 1,2,3,5-tetraoxanes (peroxide dimers) and 1,2,4,5,7,8-hexaoxonanes (peroxide trimers). (2007) Antimicrobial Agents and Chemotherapy, 51(8), 3033-3035.
  9. K. Katneni, S.A. Charman,  C.J.H. Porter. Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach. (2007) Journal of Pharmaceutical Sciences 96(2), 280-293.
  10. Y. Tang, Y. Dong, S. Wittlin, S.A. Charman, J. Chollet, F.C.K. Chiu, W.N. Charman, H. Matile, H. Urwyler, A. Dorn, S. Bajpai, X. Wang, M. Padmanilayam, J.M. Karle, R. Brun,  J.L. Vennerstrom. Weak base dispiro-1,2,4-trioxolanes: Potent antimalarial ozonides. (2007) Bioorganic & Medicinal Chemistry Letters, 17, 1260-1265. 
  11. M. McNamara, W.N. Charman, S.A. Charman. Stabilised growth hormone formulation and method of preparation thereof. European Patent Specification EO0889733 B1.
  12. J.A. Nicolazzo, S.A. Charman, W.N. Charman. Methods to assess drug permeability across the blood-brain barrier. (2006) Journal of Pharmacy and Pharmacology, 58(3) 281-293.
  13. W.N. Charman, S.A. Charman and C.J.H. Porter. Lipid based systems, drug exposure and lead optimisation. (2006) Optimizing the "Drug-like" properties of leads in the drug discovery, 131-150
  14. S. Maerki, R. Brun, S.A. Charman, A. Dorn, H. Matile, S. Wittlin. in vitro assessment of the pharmacodynamic properties and the partitioning of OZ277/RBx-11160 in cultures of plasmaodium falciparum. (2006) Journal of Antimicrobial Chemotherapy, 58, 52-58.
  15. K. Katneni, S.A. Charman and C.J.H. Porter. Impact of chromophore-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transport related events using the reciprocal permeability approach. (2006) Journal of Pharmaceutical Sciences,  96(2), 280-293.
  16. W.N. Charman, S.A. Charman and C.J.H. Porter. Contemporary Bioequivalence Issues for Poorly Water Soluble Drugs. (2006)  International Bioequivalence Standards: A New Era, 201-223.
  17. M. Padmanilayam, B. Scorneaux, Y. Dong, J. Chollet, H. Matile, S.A. Charman, D. Creek, W.N. Charman, J. S. Tomas, C. Scheurer, S. Wittlin, R. Brun, J. Vennerstrom. Antimalarial activity of N-alkyl amine, carboxamide, sulphonamide, and urea derivatives of a dispiro-1,2,4-trioxolane piperidine. (2006) Bioorganic & Medicinal Chemistry, 34(5), 5542-5545.
  18. C.S. Perry, S.A. Charman, R.J. Prankerd, F.C.K. Chiu, M.J. Scanlon, D. Chalmers and W.N. Charman. The binding interaction of synthetic ozonide antimalarials with natural and modified beta-cyclodextrins. (2006) J. Pharm. Sci., 95, 146-158.
  19. C.S. Perry, F.C.K. Chiu, K.A. McIntosh, R.J. Prankerd, W.N. Charman and S.A. Charman. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. (2006) J. Pharm. Sci., 95, 256-267.
  20. C.S. Perry, S.A. Charman, R.J. Prankerd, F.C.K. Chiu, Y. Dong, J.L. Vennerstrom, W.N. Charman.  Chemical kinetics and aqueous degradation pathways of a new class of synthetic ozonide antimalarials. (2006) J. Pharm. Sci., 95, 737-747.
  21. K. Katneni, S.A. Charman, C.J.H. Porter.  Permeability assessment of poorly water soluble compounds under solubilising conditions: The reciprocal permeability approach. (2006) J. Pharm. Sci., 95, 2170-2185.
  22. D.N. McLennan, C.J.H. Porter, G.A. Edwards, A.C. Heatherington, S.W. Martin,  S.A. Charman. The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep. (2006) Pharm. Res. 23, 2060-2066.
  23. Y. Dong, Y. Tang, J. Chollet, H. Matile, S. Wittlin, S.A. Charman, W.N. Charman, J. Santo Tomas, C. Scheurer, C. Snyder, B. Scorneaux, S. Bajpai, S.A. Alexander, X. Wang, M. Padmanilayam, C.S. Rao, R. Brun,  J.L. Vennerstrom. Effect of functional group polarity on the antimalarial activity of spiro and dispiro-1,2,4-trioxolanes. (2006) Bioorg. Med. Chem., 14, 6368-6382.
  24. Y. Dong, J, Chollet, H. Matile, S.A. Charman, F. Chiu, W.N. Charman, B. Scorneaux, H. Urwyler, J. Santo Tomas, C. Scheurer, C. Snyder, A. Dorn, X. Wang, J. Karle, Y. Tang, S. Wittlin, R. Brun,  J. Vennerstrom. Spiro and Dispiro-1,2,4-Trioxolanes as Antimalarial Peroxides: Charting a Workable Structure - Activity Relationship Using Simple Prototypes. (2005) Journal of Medicinal Chemistry, 48, 4953-4961.
  25. D. McLennan, C.J.H. Porter,  S.A. Charman.  Subcutaneous Drug Delivery and the Role of the Lymphatics. (2005)  Drug Discovery Today: Technologies 2(1) 89-96.
  26. D. Creek, F. Chiu, R. Prankerd, S.A. Charman, W.N. Charman.  Kinetics of Iron-Mediated Artemisinin Degradation: Effect of Solvent Composition and Iron Salt. (2005) Journal of Pharmaceutical Sciences, 94, 1820-1829.
  27. D.N. McLennan, C.J.H. Porter, G.A. Edwards, S.W. Martin, A.C. Heatherington,  S.A. Charman. Lymphatic absorption is the primary contributor to the systematic availability of epoetin alfa following subcutaneous administration to sheep. (2005) J. Pharmacol. Exp. Ther., 313, 345 -351.
  28. J.L. Vennerstrom, S. Arbe-Barnes, R. Brun, S.A. Charman, F.C.K. Chiu, J. Chollet, Y. Dong, A. Dorn, D. Hunziker, H. Matile, K.A. McIntosh, M. Padmanilayam, J. Santo Tomas, C. Scheurer, B. Scorneaux, Y. Tang, H. Urwyler, S. Wittlin, W. N. Charman. Identification of an antimalarial synthetic trioxolane drug development candidate.(2004) Nature, 430, 900-904.
  29. A.M. Segrave, D.E. Mager, S.A. Charman, G.A. Edwards, C.J.H. Porter. Pharmacokinetics of recombinant human leukaemia inhibitory factor in sheep. (2004) J. Pharmacol. Exp. Ther., 309, 1085-1092.
  30. D.N. McLennan, C.J.H. Porter, G.A. Edwards, M. Brumm, S.W. Martin, S.A. Charman. A pharmacokinetic model to describe the lymphatic absorption of r-metHu-Leptin after subcutaneous injection to sheep. (2003) Pharm. Res., 20, 1156-1162.
  31. S.A. Charman, D. N. McLennan, G.A. Edwards, C.J.H. Porter. Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. (2001) Pharm. Res., 18, 1620 - 1626. 
  32. C.J.H. Porter, G.A. Edwards, S.A. Charman. Lymphatic transport of proteins after SC injection: Implications of animal model selection. (2001) Adv. Drug Delivery Rev., 50, 157 - 171.
  33. A.M. Segrave, D.E. Mager, S.A. Charman, G.A. Edwards, C.J.H. Porter. Pharmacokinetics of recombinant human leukaemia inhibitory factor in sheep. (2004) J. Pharmacol. Exp. Ther., 309, 1-8.
  34. D.N. McLennan, C.J.H. Porter, G.A. Edwards, M. Brumm, S.W. Martin, S.A. Charman. A pharmacokinetic model to describe the lymphatic absorption of r-metHu-Leptin after subcutaneous injection to sheep. (2003) Pharm. Res., 20, 1156-1162.
  35. D.F. Vine, P.R. Gibson, A. Sinclair, S.A. Charman, C.J.H. Porter. Effect of dietary fatty acids on the active and passive transport properties of the rat intestine. (2002)  J. Pharm. Pharmacol., 54, 809-819.
  36. S.A. Charman, D.N. McLennan, G.A. Edwards, C.J.H. Porter. Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. (2001) Pharm. Res., 18, 1620-1626.
  37. C.J.H. Porter, G.A. Edwards, S.A. Charman. Lymphatic transport of proteins after SC injection: Implications of animal model selection. (2001) Adv. Drug Delivery Rev., 50, 157-171.
  38. C.J.H Porter and S.A. Charman. Lymphatic transport of proteins after subcutaneous administration. (2000) J. Pharm. Sci., 89, 297-310.
  39. S.A. Charman, A. Segrave, G.A. Edwards, and C.J.H. Porter. Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection. (2000) J. Pharm. Sci., 89, 168-177.